| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/26/2008 | US7335154 Radiotherapy |
| 02/26/2008 | CA2322195C Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| 02/26/2008 | CA2317044C Medicament for neurodegenerative diseases |
| 02/26/2008 | CA2300910C Phosphono-carboxylate compounds for treating amyloidosis |
| 02/26/2008 | CA2200761C Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
| 02/21/2008 | WO2008022286A2 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 02/21/2008 | WO2008021545A2 Modulators of muscarinic receptors |
| 02/21/2008 | WO2008021532A2 Treatment of inflammatory diseases |
| 02/21/2008 | WO2008021518A2 Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride |
| 02/21/2008 | WO2008021463A2 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 02/21/2008 | WO2008021375A2 Modulators of muscarinic receptors |
| 02/21/2008 | WO2008020802A1 Cardioprotective compounds |
| 02/21/2008 | WO2008020799A1 Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists |
| 02/21/2008 | WO2008020778A1 Analgetically active peptide family |
| 02/21/2008 | WO2008020748A1 Analgesic aromatic product |
| 02/21/2008 | WO2008020651A1 P2x4 receptor antagonist |
| 02/21/2008 | WO2008020625A1 Dibenzoylmethane compound and pharmaceutical composition comprising the compound as active ingredient |
| 02/21/2008 | WO2008020622A1 NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND |
| 02/21/2008 | WO2008020306A2 Isoindole derivatives |
| 02/21/2008 | WO2008020302A2 Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| 02/21/2008 | WO2008020255A1 Benzo[1,2,3]thiadiazine derivatives |
| 02/21/2008 | WO2008020150A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 02/21/2008 | WO2008020055A1 Novel isoindol derivatives as ep4 receptor agonists |
| 02/21/2008 | WO2008019823A2 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins |
| 02/21/2008 | WO2008019769A1 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10- hydroxydecy l)-1,4-benzoquinone |
| 02/21/2008 | WO2008019594A1 Agmatine sulfate dihydrate and its medicinal use |
| 02/21/2008 | WO2008019588A1 A chinese medicine composition for treating depression, neurasthenia and process thereof |
| 02/21/2008 | WO2008019572A1 Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof |
| 02/21/2008 | WO2008019431A1 Method and compositions for simultaneously regulating memory and mood |
| 02/21/2008 | WO2008005577A3 Compositions of polyphenols and methods of use |
| 02/21/2008 | WO2008000951A3 Urea derivatives of tropane, their preparation and their therapeutic application |
| 02/21/2008 | WO2008000743A3 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| 02/21/2008 | WO2007149451A3 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
| 02/21/2008 | WO2007146116A3 Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| 02/21/2008 | WO2007130860A3 Constrained compounds as cgrp-receptor antagonists |
| 02/21/2008 | WO2007128088A3 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases |
| 02/21/2008 | WO2007121389A3 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors |
| 02/21/2008 | WO2007112065A3 Methods for treating cognitive and other disorders |
| 02/21/2008 | WO2007110243A8 Medicament, cosmetic or food product comprising an indol compound, the use thereof and the method of isolation thereof from sauerkraut |
| 02/21/2008 | US20080045610 Methods for regulating neurotransmitter systems by inducing counteradaptations |
| 02/21/2008 | US20080045607 Compositions and Methods for Treatment of Protein Misfolding Diseases |
| 02/21/2008 | US20080045603 Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity |
| 02/21/2008 | US20080045588 Preparation and utility of substituted amphetamines |
| 02/21/2008 | US20080045583 Stable levetiracetam compositions and methods |
| 02/21/2008 | US20080045571 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/21/2008 | US20080045558 opiod and/or N-methylaspartic acid receptor modulators, used for the treatment and/or management of pain, neurodegenerative diseases, drug abuse and dependence, vision defects, or as muscle relaxants, antitussive and anxiolytic agents |
| 02/21/2008 | US20080045551 Pharmaceutical combination comprising an adenosine a1 antagonist and a radiocontrast media |
| 02/21/2008 | US20080045547 Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use |
| 02/21/2008 | US20080045543 6-(2-Benzyl-piperazin-1-yl)-1H-indole, used as serotonin, norepinephrine or dopamine reuptake inhibitors; antidepressants; anxiolytic agents; monoamine reuptake inhibitors |
| 02/21/2008 | US20080045539 such as 5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole, having nicotinic receptors modualtory activity, used for the treatment of attention deficit disorder, senile dementia, Down's syndrome, amyotrophic lateral sclerosis, Huntington's, Pick's and Alzheimer's disease |
| 02/21/2008 | US20080045534 Derivatives of 1,3-diamino benzene as potassium channel modulators |
| 02/21/2008 | US20080045533 Novel cyclohexyl sulphones |
| 02/21/2008 | US20080045532 schizophrenia; 1-[4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole; administered alone or with another antipsychotic drug |
| 02/21/2008 | US20080045527 Immunomodulating Heterocyclic Compounds |
| 02/21/2008 | US20080045525 Piperazinyl-Pyridine Analogues |
| 02/21/2008 | US20080045524 Selective NPY (Y5) antagonists |
| 02/21/2008 | US20080045515 To treat Alzheimer's disease; compounds with an additional fused ring containing an SO2 group; to suppress or attenuate the secretion of beta -amyloid; (4aSR,6RS,8aSR)-6-[(4-chlorophenyl)sulfonyl]-6-(2,5-difluorophenyl)-3-ethyloctahydro-1H-2,1,3-benzothiadiazine 2,2-dioxide; cyclization, alkylation |
| 02/21/2008 | US20080045510 Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| 02/21/2008 | US20080045509 Substituted benzyl amine compounds |
| 02/21/2008 | US20080045508 Substituted aminomethyl benzamide compounds |
| 02/21/2008 | US20080045507 Substituted benzamide modulators of the histamine h3 receptor |
| 02/21/2008 | US20080045506 Pyrrolidine Derivatives as Histamine Receptors Ligands |
| 02/21/2008 | US20080045503 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/21/2008 | US20080045500 Nerve Regeneration Stimulator |
| 02/21/2008 | US20080045499 Preferential Inhibition of Presenilin-1 |
| 02/21/2008 | US20080045493 such as Parkinson's disease, schizophrenia, cognitive disorders, depression, anxiety, drug addiction, eating disorders and urogenital disorders; 4-(2,2-Difluoro-cyclopropyl)-N-[4-(1-propyl-piperidin-3-yl)-phenyl]-benzenesulfonamide |
| 02/21/2008 | US20080045489 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 02/21/2008 | US20080045455 RAGE fusion proteins, formulations, and methods of use thereof |
| 02/21/2008 | US20080044499 Sleep Improvement Composition |
| 02/21/2008 | US20080044495 Extract of plant Dendrobii Caulis and preparing process thereof |
| 02/21/2008 | US20080044485 increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures; microparticles; drugs such as risperidone |
| 02/21/2008 | US20080044478 Preparation of injectable suspensions having improved injectability |
| 02/21/2008 | US20080044473 Methods of reducing nervous system glial scar formation using cyclosporine components |
| 02/21/2008 | US20080044471 Neurotherapeutic compositions |
| 02/21/2008 | US20080044463 Bradykinin B2 Receptor Antagonist Peptide From Amphibian Skin |
| 02/21/2008 | US20080044428 Glycosylphosphatidylinositol Glycan Signalling Via Integrins Functioning as Glycan Specific Receptors |
| 02/21/2008 | US20080044425 Polypeptides having phospholipase a2 activity |
| 02/21/2008 | US20080044423 Compounds |
| 02/21/2008 | US20080044392 Isolation of Stem Cell-Like Cells and Use Thereof |
| 02/21/2008 | US20080044390 Methods and compositions for the treatment of neurodegenerative disorders |
| 02/21/2008 | US20080044355 including cystic fibrosis transmembrane conductance regulator ("CFTR"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease |
| 02/21/2008 | US20080044354 Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation |
| 02/21/2008 | US20080044349 Therapeutic and diagnostic applications of perlecan domain I splice variants |
| 02/21/2008 | US20080042818 Trailer tire alert system |
| 02/21/2008 | DE102007004991A1 Use of biocomplex preparation (from reaction pattern in vertebrate cells) for the treatment of apoplexia and acute circulatory disorders |
| 02/21/2008 | CA2675244A1 Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia |
| 02/21/2008 | CA2661082A1 Benzo[1,2,3]thiadiazine derivatives |
| 02/21/2008 | CA2661014A1 Cardioprotective compounds |
| 02/21/2008 | CA2661003A1 Crystalline forms of tiagabine hydrochloride |
| 02/21/2008 | CA2660974A1 Modulators of muscarinic receptors |
| 02/21/2008 | CA2660903A1 Modulators of muscarinic receptors |
| 02/21/2008 | CA2660880A1 Treatment of inflammatory diseases |
| 02/21/2008 | CA2660474A1 Arylpiperazine derivatives and uses thereof |
| 02/21/2008 | CA2660441A1 Imidazole amines as inhibitors of .beta.-secretase |
| 02/21/2008 | CA2659424A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 02/21/2008 | CA2659299A1 Azetidine compounds |
| 02/20/2008 | EP1889911A2 An antisense oligonucleotide preparation method |
| 02/20/2008 | EP1889905A1 Method for amelioration of disease condition induced by mood disorder |
| 02/20/2008 | EP1889639A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 02/20/2008 | EP1889623A2 Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics |